HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NVAX
Novavax, Inc.
NVAX lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NVAX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
NVAX's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NVAX PE Valuation
NVAX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 116x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NVAX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
NVAX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NVAX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.08 | — |
| Q3 2026 | -$0.29 | -115% |
| Q2 2026 | -$1.35 | -157% |
| Q1 2026 | -$0.41 | -115% |
| Q4 2025 | $2.58 | +$3.81 |
| Q3 2025 | $1.89 | +$4.03 |
| Q2 2025 | $2.38 | +$5.02 |
| Q1 2025 | $2.75 | +$5.80 |
| Q4 2024 | -$1.23 | +$4.18 |
NVAX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NVAX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NVAX on profitability, with a higher operating margin.
NVAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $68.3M | -3% |
| Q2 2026 | $56.7M | -76% |
| Q1 2026 | $139.5M | -79% |
| Q4 2025 | $147.1M | +67% |
| Q3 2025 | $70.4M | -17% |
| Q2 2025 | $239.2M | -42% |
| Q1 2025 | $666.7M | +610% |
| Q4 2024 | $88.3M | -70% |
NVAX's revenue has slid since its 2022 peak: $68M last quarter, down 3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -46% | +207 points |
| Q2 2026 | -97% | -139 points |
| Q1 2026 | -11% | -88 points |
| Q4 2025 | 9.7% | +158 points |
| Q3 2025 | -253% | -94 points |
| Q2 2025 | 42% | +3.5 points |
| Q1 2025 | 77% | +232 points |
| Q4 2024 | -148% | -85 points |
NVAX's operating margin was −46% last quarter, up 207 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NVAX on cash generation, producing positive trailing cash flow while its opponent burns cash.
NVAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$95.3M | -190% |
| Q2 2026 | -$73.4M | +$54.3M |
| Q1 2026 | -$33.7M | +$153M |
| Q4 2025 | -$41.6M | +$133.5M |
| Q3 2025 | $105.8M | +$252M |
| Q2 2025 | -$127.7M | -141% |
| Q1 2025 | -$186.7M | -$96.3M |
| Q4 2024 | -$175.1M | +$10.5M |
NVAX has burned cash in most quarters: −$244M over the past year, against −$384M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NVAX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NVAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +350K shares |
| 1 year | +1.6% | +2.6M shares |
| 3 years | +58% | +60.9M shares |
| 5 years | +123% | +90.8M shares |
| Available history | +584% | +141M shares |
NVAX has 165M diluted shares, up 1.6% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over NVAX on leverage, with a lower net debt burden relative to earnings.
NVAX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
NVAX's net debt is less than a year of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NVAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.4 | Neutral |
| Stochastic | 41.0 | Neutral |
NVAX's weekly RSI is 46 (neutral) and its Stochastic is 41 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NVAX PE vs Healthcare Sector
| Metric | NVAX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NVAX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NVAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.6 | 17% below |
| 20 week MA | $9.52 | 8% below |
| 50 week MA | $8.98 | 2.4% below |
| 100 week MA | $8.32 | 5.3% above |
| 200 week MA | $8.39 | 4.4% above |
NVAX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NVAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.99 | $129.3 | +3142% |
| 2021 | $129.3 | $177.3 | +37% |
| 2022 | $177.3 | $9.66 | -95% |
| 2023 | $9.66 | $4.80 | -50% |
| 2024 | $4.80 | $8.28 | +72% |
| 2025 | $8.28 | $6.83 | -18% |
| 2026 YTD | $6.83 | $8.76 | +28% |
NVAX has the edge over HIMS on returns for 2026, with the stronger performance.